KZIA.US Kazia Therapeutics Ltd ADR

Healthcare Biotechnology USA Stocks
6.62 USD
Close of Nov 15, 2026
4.86 17.40
Market cap
USD 75.6M
P/E
-
P/B
3.24x
ROE
-96.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Dec 2025.

Is KZIA.US undervalued?

Graham number

The Graham number of Kazia Therapeutics Ltd ADR cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kazia Therapeutics Ltd ADR fundamental analysis

No fundamental analysis for Kazia Therapeutics Ltd ADR yet.

Kazia Therapeutics Ltd ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kazia Therapeutics Ltd ADR

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous…

Full company profile